(0.10%) 5 332.50 points
(0.02%) 40 145 points
(0.18%) 18 669 points
(-0.45%) $79.70
(0.84%) $2.65
(1.11%) $2 444.30
(3.19%) $32.26
(0.06%) $1 090.70
(0.01%) $0.920
(-0.07%) $10.67
(0.03%) $0.787
(-0.51%) $90.50
Live Chart Being Loaded With Signals
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China...
Stats | |
---|---|
Today's Volume | 212.00 |
Average Volume | 9.00 |
Market Cap | 0.00 |
Last Dividend | $0.0297 ( 2021-09-16 ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.604 |
ATR14 | $0 (0.00%) |
Epigenomics AG Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Epigenomics AG Financials
Annual | 2021 |
Revenue: | $6.20M |
Gross Profit: | $6.07M (97.81 %) |
EPS: | $-0.271 |
FY | 2021 |
Revenue: | $6.20M |
Gross Profit: | $6.07M (97.81 %) |
EPS: | $-0.271 |
FY | 2020 |
Revenue: | $842 000 |
Gross Profit: | $697 000 (82.78 %) |
EPS: | $-2.48 |
FY | 2019 |
Revenue: | $1.13M |
Gross Profit: | $872 000 (77.51 %) |
EPS: | $-4.48 |
Financial Reports:
No articles found.
Epigenomics AG Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.833 | 2018-10-31 |
Last Dividend | $0.0297 | 2021-09-16 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 5 | -- |
Total Paid Out | $2.72 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.55 | -- |
Div. Sustainability Score | 0.458 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SEBC | Ex Dividend Knight | 2023-08-30 | Quarterly | 0 | 0.00% | |
ERMAY | Ex Dividend Junior | 2023-05-25 | Sporadic | 0 | 0.00% | |
MCEM | Ex Dividend King | 2023-08-25 | Quarterly | 0 | 0.00% | |
BURCA | Ex Dividend Knight | 2023-08-14 | Quarterly | 0 | 0.00% | |
TBLMY | Ex Dividend Junior | 2023-07-06 | Annually | 0 | 0.00% | |
GBOOY | Ex Dividend Junior | 2023-06-15 | Annually | 0 | 0.00% | |
NWYF | Ex Dividend Junior | 2023-08-04 | Semi-Annually | 0 | 0.00% | |
CMWAY | Ex Dividend Junior | 2023-08-18 | Semi-Annually | 0 | 0.00% | |
UEPCP | Ex Dividend Knight | 2023-07-20 | Quarterly | 0 | 0.00% | |
HONT | Ex Dividend Junior | 2023-08-14 | Quarterly | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.391 | 1.500 | -7.83 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.0984 | 1.200 | -3.28 | -3.94 | [0 - 0.3] |
returnOnEquityTTM | -0.187 | 1.500 | -3.19 | -4.78 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 11.06 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 10.72 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 10.72 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0187 | -1.500 | 9.69 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -45.35 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.463 | 2.00 | -0.154 | -0.309 | [0 - 30] |
freeCashFlowPerShareTTM | -0.467 | 2.00 | -0.233 | -0.467 | [0 - 20] |
debtEquityRatioTTM | 0.0208 | -1.500 | 9.92 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.978 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.380 | 1.000 | -9.60 | -9.60 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -9.03 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.252 | 0.800 | -1.657 | -1.325 | [0.5 - 2] |
Total Score | 0.458 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -8.11 | 1.000 | -0.920 | 0 | [1 - 100] |
returnOnEquityTTM | -0.187 | 2.50 | -2.05 | -4.78 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.467 | 2.00 | -0.156 | -0.467 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.463 | 2.00 | -0.154 | -0.309 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.463 | 1.500 | -6.42 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.669 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.63 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Epigenomics AG
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators